Insulin icodec: A novel once-weekly treatment for diabetes

IF 3.2 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2024-07-24 DOI:10.1111/dme.15414

Hannah Schaffner, Jordyn Wiener, Amanda DeLuca, Ariana Genovese, Alexander Deeb, Wasim Deeb, Mae Sheikh-Ali, David Sutton, Ashwini Gore, Jason Berner, Jessica Huston, Rebecca Goldfaden

{"title":"Insulin icodec: A novel once-weekly treatment for diabetes","authors":"Hannah Schaffner, Jordyn Wiener, Amanda DeLuca, Ariana Genovese, Alexander Deeb, Wasim Deeb, Mae Sheikh-Ali, David Sutton, Ashwini Gore, Jason Berner, Jessica Huston, Rebecca Goldfaden","doi":"10.1111/dme.15414","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To summarize the results of clinical studies of insulin icodec, an investigational insulin analog designed for once-weekly administration, in adults with type 1 and type 2 diabetes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Thirteen published articles describing clinical studies of insulin icodec were identified in PubMed, and data pertinent to key study outcomes were selected for inclusion in this review.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In insulin-naïve and insulin-treated individuals, icodec demonstrated efficacy in glycaemic control superior or noninferior to that of insulins glargine U100, glargine U300 and degludec. Icodec exhibited a safety profile comparable to marketed insulins, with the exception of hypoglycaemic event rates.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>As a once-weekly alternative to daily basal insulin, icodec is expected to improve patient adherence and satisfaction, reducing the required number of injections per year from 365 to 52 and providing a dosing option potentially attractive to a wide range of insulin users. However, clinical data suggest a notable risk of hypoglycaemia with weekly icodec administration, especially in individuals with type 1 diabetes.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.15414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To summarize the results of clinical studies of insulin icodec, an investigational insulin analog designed for once-weekly administration, in adults with type 1 and type 2 diabetes.

Methods

Thirteen published articles describing clinical studies of insulin icodec were identified in PubMed, and data pertinent to key study outcomes were selected for inclusion in this review.

Results

In insulin-naïve and insulin-treated individuals, icodec demonstrated efficacy in glycaemic control superior or noninferior to that of insulins glargine U100, glargine U300 and degludec. Icodec exhibited a safety profile comparable to marketed insulins, with the exception of hypoglycaemic event rates.

Conclusions

As a once-weekly alternative to daily basal insulin, icodec is expected to improve patient adherence and satisfaction, reducing the required number of injections per year from 365 to 52 and providing a dosing option potentially attractive to a wide range of insulin users. However, clinical data suggest a notable risk of hypoglycaemia with weekly icodec administration, especially in individuals with type 1 diabetes.

查看原文本刊更多论文

胰岛素 icodec：每周一次的新型糖尿病治疗方法。

目的：总结针对1型和2型糖尿病成人患者的胰岛素icodec临床研究结果：在PubMed上找到了13篇关于胰岛素icodec临床研究的发表文章，并选择了与主要研究结果相关的数据纳入本综述：结果：在胰岛素新药和胰岛素治疗的患者中，icodec 在血糖控制方面的疗效优于或不低于格列宁 U100、格列宁 U300 和 degludec。除低血糖事件发生率外，Icodec 的安全性与市售胰岛素相当：作为日用基础胰岛素的一周一次替代品，icodec有望提高患者的依从性和满意度，将每年所需的注射次数从365次减少到52次，并为广大胰岛素使用者提供了一种具有潜在吸引力的剂量选择。然而，临床数据表明，每周注射 icodec 有明显的低血糖风险，尤其是对 1 型糖尿病患者而言。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”